Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 7/20 | 0.60 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | RXRB | P28702 | 2/20 | 0.56 |
| ▸ | RXRG | P48443 | 2/20 | 0.56 |
| ▸ | THRA | P10827 | 1/20 | 0.49 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30440465 | 1.00 | CREBBP (0.60) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL30440212 | 0.88 | THRA (0.56) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL17386686 | 0.88 | THRA (0.56) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL312486 | 0.88 | CREBBP (0.56) | CREBBPRXRARXRBRXRGCYP1A2 | |
| SCHEMBL313614 | 0.88 | CYP2C9 (0.48) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL1402196 | 0.88 | TSHR (0.60) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL16960225 | 0.87 | RXRA (0.51) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL17407193 | 0.87 | THRA (0.61) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL17339621 | 0.86 | RXRA (0.54) | CREBBPRXRARXRBRXRGTHRA | |
| SCHEMBL10323654 | 0.85 | RXRA (0.45) | CREBBPRXRARXRBRXRGTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110845490-B | 2-acylaminothiazole derivative or salt thereof | 旭飞药业股份有限公司 | 2023-03-28 | — | — | CN | disclosed |
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| US-RE49111-E1 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2022-06-21 | — | — | US | disclosed |
| CN-110845490-A | 2-acylaminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2020-02-28 | — | — | CN | disclosed |
| CN-106414438-B | 2-acylaminothiazole derivative or salt thereof | 安斯泰来制药株式会社 | 2019-12-31 | — | — | CN | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-2963036-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE AND SALT THEREOF | ASTELLAS PHARMA INC (JP) | 2019-08-28 | — | — | EP | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| EP-3153511-B1 | 2-ACYLAMINOTHIAZOLE DERIVATIVE FOR USE IN THE PREVENTION OR TREATMENT OF BLADDER/URINARY TRACT DISEASES | ASTELLAS PHARMA INC (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-9951060-B2 | 2-acylaminothiazole derivative or salt thereof | ASTELLAS PHARMA INC. (JP) | 2018-04-24 | — | — | US | disclosed |
| WO-2007039439-A1 | OXADIAZOLYL PYRAZOLO-PYRIMIDINES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-04-12 | — | — | WO | disclosed |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | HOFFMANN-LA ROCHE INC. | 2007-03-29 | — | — | US | disclosed |
| EP-1761541-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2007-03-14 | — | — | EP | disclosed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| EP-1670801-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. Hoffmann-Roche AG (CH) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005123738-A1 | PYRRAZOLO-PYRIMIDINE DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2005-12-22 | — | — | US | disclosed |
| US-20050130992-A1 | Pyrazolo-pyridine | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-16 | — | — | US | disclosed |
| WO-2005040171-A1 | PYRAZOLO AND IMIDAZO-PYRIMIDINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282827-A1 | Pyrazolo-pyrimidine derivatives | P2RX3, P2RX1, P2RX5 | CREBBP 1528/4885RXRA 1978/4885RXRB 1980/4885 |
| US-20050130992-A1 | Pyrazolo-pyridine | CHRM2, CHRM1, QDPR | CREBBP 1394/4885RXRA 1882/4885RXRB 1581/4885 |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | GRM1, GRM2, GRM3 | CREBBP 1236/4885RXRA 113/4885RXRB 108/4885 |
| US-20070072879-A1 | Novel compounds as metabotropic glutamate receptor antagonists | GRM1, GRM2, GRM3 | CREBBP 2377/4885RXRA 598/4885RXRB 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.